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Inhibitors of ADP-ribosylation inhibited the myeloid differentiation of murine myelomonocytic leukemia, WEHI-3BD+ 
cells induced by granulocyte colony-stimulating factor. Benzamide, at 2.0 mM, inhibited 50% of the WEHI-3BD+ cell 
differentiation but had no significant effect on the proliferation. However, benzylaminododecylguanine hydrochloride 
and p-methoxylbenzylaminodecamethylene guanidine sulfate at 2.0 and 2.2 PM, respectively, inhibited 50% of prolifera- 
tion but had no effect at all on differentiation. The differential effects of inhibitors provide a model to study the role 
of ADP-ribosylation in myeloid differentiation. 
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1. INTRODUCTION 
ADP-ribosylation is a post-translational 
modification process that transfers the ADP- 
ribose residue from NAD+ to acceptor proteins. It 
has been suggested that this process plays an im- 
portant regulatory role in cellular proliferation and 
differentiation [ 11. The membrane-associated 
stimulatory (G,) and inhibitory (Gi) components of 
adenylate cyclase can act as ADP-ribose acceptors 
for cholera toxin and pertussis toxin, respectively 
[2], thus activating adenylate cyclase. Chromatin 
proteins can be ADP-ribosylated by a nuclear 
ADP-ribosyl transferase which is activated by 
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DNA strand breaks [3]. This modification of 
chromatin has been suggested as playing an impor- 
tant role in DNA repair and cell differentiation [4]. 
Studies on the possible role of ADP-ribosylation in 
myeloid differentiation are limited. Francis et al. 
[5] have reported that inhibitors of ADP- 
ribosylation such as 3-methoxybenzamide inhibit 
monocyte differentiation of human bone marrow 
progenitor cells as assayed in soft-agar for colony 
formation. Colon-Otero et al. [6] also reported 
that 3-aminobenzamide and nicotinamide caused a 
significant dose-response inhibition of interleukin- 
3 induced FDCP-1 cell proliferation. Dexter et al. 
[7] have used two compounds, BADGH and 
MBAMG [8], which are potent inhibitors of mono 
ADP-ribosylation to study their effect on myeloid 
differentiation of long-term murine bone marrow 
cell cultures. Their results have shown that these 
inhibitors can block the differentiation of commit- 
ted myeloid progenitor cells. Results from these 
studies indicated the involvement of ADP-ribo- 
sylation in the myeloid differentiation. However, 
whether the effect is on the proliferation or dif- 
ferentiation step of the process has not been 
elucidated. 
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In this communication, we report the differen- 
tial effect of various ADP-ribosylation inhibitors 
on the differentiation of a murine myelomonocytic 
leukemia cell line induced by granulocyte colony- 
stimulating factor. This system will provide a 
model to study the role of ADP-ribosylation in 
myeloid differentiation. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Murine myelomonocytic leukemia cell line WEHL3BD+ was 
kindly provided by Dr Malcolm AS. Moore of Sloan Kettering 
Cancer Center, New York, and was cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal calf 
serum. Cells between passage 12 and 30 were used in the ex- 
periments. 
2.2. Soft-agar assay of bone marrow stem cell differentiation 
The standard procedure of colony formation by bone mar- 
row cells was conducted as described previously [9] to assess the 
effects of ADP-ribosylation inhibitors on myeloid differentia- 
tion. The ADP-ribosylation inhibitors including benzamide, 
3-aminobenzamide, 3-methoxybenzamide, 5methylnicotin- 
amide, BADGH and MBAMG at different concentrations were 
added to the cultures in the beginning of the assay. The number 
of colonies was counted at day 5. Endotoxin-treated mouse lung 
conditioned medium was used as a source for GM-CSF and G- 
CSF. The morphology of cells in colonies was examined by 
staining the plates with hematoxylin according to procedures 
previously reported [lo]. 
2.3. Differentiation of WEHI-3BD+ cells induced by mouse 
lung conditioned medium 
The WEHI-3BD+ cells were seeded in 35 mm petri-dishes at 
300 cells/plate containing 1 ml of 0.3% agar in DME-S (10% 
fetal calf and horse sera). Endotoxin-treated mouse lung condi- 
tioned medium was added as the source of G-CSF to the culture 
at the beginning of the assay along with ADP-ribosylation in- 
hibitors at different concentrations. The plates were incubated 
at 37°C in a humidified incubator with 7% CO2 for 7 days. 
Total number of colonies and number of dispersed colonies 
were scored separately under a dissection stereomicroscope and 
the differentiation activity was expressed as percent of dispersed 
colonies [ 111. 
2.4. Liquid culture assay of WEHI-3BD’ cell differentiation 
Suspension cultures of WEHL3BD cells were seeded at 1.8 x 
lo5 cells/ml in DME medium supplemented with 10% FCS. 
Endotoxin-treated mouse lung conditioned medium (2000 U/ 
ml, G-CSF), benzamide (2 mM) and MBAMG (2 FM) were 
added to the cultures either separately or in combination with 
proper control. The cells were cultured at 37°C in a humidified 
incubator with 7% CO2 for 4 days. The total cell numbers were 
counted and cells under different treatment were washed and 
assayed for colony formation as described in section 2.3. 
3. RESULTS 
3.1. Inhibition of colony formation by inhibitors 
of ADP-ribosylation 
Colony formation of bone marrow cells in a 
soft-agar assay was inhibited by two different 
groups of ADP-ribosylation inhibitors. As shown 
in table 1, analogs of NAD+ including benzamide, 
3_aminobenzamide, 3-methoxybenzamide and 
5-methylnicotinamide inhibited colony formation 
in the millimolar range. The concentration of in- 
hibitor that resulted in 50% inhibition of colony 
formation was between 1.6 mM for 3-methoxy- 
benzamide and 6.0 mM for 3-aminobenzamide. 
The guanidine derivatives, BADGH and 
MBAMG, which are analogs of arginine residues 
in acceptor proteins, have shown a much more po- 
tent inhibitory activity. The concentration of 
BADGH and MBAMG that resulted in 50% in- 
hibition of colony formation were 1.7 and 1.1 pM, 
respectively. Morphological analysis of colonies 
formed in the presence of ADP-ribosylation in- 
hibitors indicated that macrophage colony forma- 
tion was preferentially sensitive to the inhibitors as 
reported by Francis et al. [5]. 
3.2. Effect of benzamide on differentiation of 
WEHI-3BD+ 
In order to study the effect of ADP-ribosylation 
inhibitors on differentiation of myelogenous 
leukemia cells, benzamide at different concentra- 
tions was added to the assay plates. The 
WEHI-3BD+ cells form compact and tight col- 
onies in the soft-agar plates. However, in the 
presence of G-CSF, the leukemia cells differentiate 
and form dispersed colonies [12]. The dispersed 
colony formation assay was used as standard assay 
method for G-CSF activity [12]. As shown in fig. 1, 
Table 1 
Concentration of inhibitors at 50% inhibition of colony 
formation 
Compound Concentration (mM) 
Benzamide 2.1 
3-Aminobenzamide 6.0 
3-Methoxybenzamide 1.6 
S-Methylnicotinamide 3.1 
MBAMG 0.0011 
BADGH 0.0017 
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Fig. 1. The effect of benzamide on colony formation. Different 
concentrations of benzamide were added to the soft-agar assay 
plates with standard amounts of E-MLCM (50 pl). The colony 
formation assay was conducted as described in section 2. Total 
number of colonies and number of dispersed colonies were 
scored. Percent of total colonies in control (w); percent of 
dispersed colonies in control (M). 
benzamide, at concentrations up to 2.0 mM, did 
not show significant inhibition of total colony for- 
mation. However, a 50% inhibition of dispersed 
colony formation was observed. There are no ob- 
vious changes in colony size (>500 cells) at this 
concentration of benzamide. The results indicated 
that benzamide at 2 mM preferentially inhibited 
the differentiation without significant effect on the 
proliferation. At a high concentration of 10 mM, 
benzamide completely inhibited the colony forma- 
tion. Reduced colony size (< 100 cells) was ob- 
served at 5 mM benzamide. 
3.3. Effect of MBAMG and BADGH on colony 
formation and differentiation of 
WEHI-3BD+ 
In contrast to the effect of benzamide, the 
arginine analogs of MBAMG and BADGH exerted 
a different effect on the WEHI-3BD+ cells in the 
soft-agar assay. As shown in fig.2, MBAMG in- 
hibited the colony formation of WEHI-3BD+ cells 
at a much lower concentration than benzamide. It 
inhibited 50% of colonies formation at 2 PM and 
12345 0 
MBAMG ( p M) 
Fig.2 The effect of MBAMG on colony formation. The 
experiment was carried out as described in fig.1, except 
MBAMG at different concentrations was added instead of 
benzamide. Percent of total colonies in control (o---o); 
percent of dispersed colonies in control (M). 
inhibited completely the colony formation at 
10,~M. Although the number of colony was in- 
hibited, the percent dispersed colonies remained 
about the same. There are no colony size (>500 
cells) changes up to 1 mM of MBAMG, however, 
colony size reduced to less than 100 cells aggregates 
when 2.5 ,uM or greater MBAMG was added. This 
is in contrast to the benzamide inhibition where 
differentiation was preferentially inhibited. 
BADGH had the same effect as MBAMG on the 
colony formation of WEHI-3BD+ cell (not 
shown). 
3.4. Differentiation of WEHI-3BD+ cells in 
suspension culture 
As shown in table 2, when WEHI-3BD+ cells 
were cultured in DME medium supplemented with 
10% FCS, the growth was inhibited by the E- 
MLCM. Benzamide at 2.0 mM did not show 
significant inhibition as observed previously in the 
soft-agar assay. Based on the observation that dif- 
ferentiated cells could not form colonies in the 
soft-agar, the culture cells treated with different in- 
hibitors and E-MLCM were washed and assayed 
on soft-agar as described in section 2. The number 
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Table 2 
Effects of E-MLCM, benzamide on WEHI-3BD’ cells in 
suspension culture 
Total viable Number 
cell number of colonies 
(x 106) 
Control 
E-MLCM (2000 units/ml) 
Benzamide (2 mM) 
Benzamide (2 mM) + E-MLCM 
4.2 123 i 19 
1.9 0 
4.0 130 f 21 
(2000 units/ml) 2.0 1292 5 
of colonies are shown in the last column of table 
2. E-MLCM-treated cells, although showing only 
50% growth inhibitions, could not form any col- 
onies at all, indicating complete differentiation of 
the cells. Morphological study of the E-MLCM 
treated has indicated extensive (79%) mor- 
phological changes to mature monocyte-like cells 
typically with increasing cytoplasmic to nucleus 
ratio as reported previously [12]. However, when 
benzamide at 2 mM was added to the culture, cell 
differentiation was inhibited and the cells in the 
culture were able to form colonies as in the con- 
trol. This result further supports that benzamide, 
at 2 mM, preferentially inhibited the differentia- 
tion of WEHI-3BD cells as shown in the soft-agar 
assay. 
4. DISCUSSION 
CSFs are a group of proteins required for the 
differentiation and maturation of macrophages 
and granulocytes from bone marrow stem cells 
[ 131. Great advances have been accomplished 
recently largely due to the recombinant DNA 
techniques and their application to the cloning and 
expression of CSF genes [14]. However, the 
mechanism of action of CSF has not been fully 
understood. Since ADP-ribosylation is one of the 
regulatory reactions involved in cell proliferation 
and differentiation, the possible role of ADP- 
ribosylation in myeloid differentiation has been 
implicated. It is clear from the results presented 
here that inhibitors of ADP-ribosylation inhibit 
the colony formation from bone marrow stem cells 
as assayed on the soft-agar. Benzamide and its 
derivatives inhibited the colony formation in the 
range of l-5 mM. The macrophage colonies were 
preferentially inhibited. This observation was 
similar to the results of Francis et al. [5] on the 
human marrow assay. The sensitivity of colony 
formation of bone marrow cells to the inhibitors 
was compatible in human and murine. However, 
the question of whether ADP-ribosylation in- 
hibitors affect the proliferation or differentiation 
step cannot be answered by the bone marrow cell 
experiment. A murine myelomonocytic leukemia 
cell line WEHI-3BD+, which can be induced by 
endotoxin-mouse lung conditioned medium to 
undergo terminal differentiation, was used in these 
experiments to study the effect of benzamide on 
the proliferation and differentiation. The results 
shown in fig.1 have indicated that benzamide at 
2 mM inhibited the myeloid differentiation with 
minimal effect on the proliferation as shown by 
colony formation. Recent results from an in vivo 
study [ 151 have shown that benzamide at 
millimolar concentration inhibited the mono ADP- 
ribosyl transferase activity while the poly ADP- 
ribosyl polymerase was inhibited by benzamide at 
concentrations in the micromolar range. These 
data suggest hat mono ADP-ribosylation may be 
one of the key regulatory mechanisms in myeloid 
differentiation. In contrast, studies on the effects 
of MBAMG and BADGH have indicated that 
these two inhibitors inhibited proliferation without 
any effect on differentiation (fig.2). Since 
MBAMG and BADGH are the analogs of arginine 
derivatives erving as artificial acceptors for mono 
ADP-ribosylation, this will suggest that mono 
ADP-ribosylation of arginine-protein acceptors is 
not involved in the myeloid differentiation. The 
differentiation of the WEHI-3BD+ cell presented 
in this article provides a model system to in- 
vestigate further the role of ADP-ribosylation in 
myeloid differentiation. 
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